查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1423568

到 2030 年非注射胰岛素市场预测：按产品、剂量、分销管道和地区进行的全球分析

Non-Injectable Insulin Market Forecasts to 2030 - Global Analysis By Product (Oral, Transdermal, Nasal, Sublingual and Other Products), Dosage, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球非注射胰岛素市场规模将达到 14 亿美元，预计到 2030 年将达到 40 亿美元，预测期内复合年增长率为 15.2%。

非注射型胰岛素是指不需要将针头插入皮肤，而是可以用其他方法给药的胰岛素型态。这些技术可以作为贴剂局部应用，也可以透过吸入、口服药物或鼻喷剂来应用。随着非注射胰岛素的引入，需要胰岛素治疗的人将有一个更方便的选择，这可能会提高治疗医嘱遵从性并全面改善生活品质。

据 Biocon 称，口服胰岛素製剂 Tregopil 用于 1 型糖尿病的 1 期试验已于 2022 年 6 月结束，但用于第 2 型糖尿病的 3 期试验仍在继续。

药物传输技术开发

药物输送技术的不断进步是市场成长的主要驱动力。由于这些创新技术的进步，糖尿病管理领域正在发生变化，使非注射胰岛素替代品更加可靠、高效，并且对患者和医疗保健专业人员都有吸引力。我就是。此外，这些发展正在提高胰岛素剂量的准确性和一致性，并提高非注射胰岛素装置的整体有效性。

副作用

与任何药物一样，非注射胰岛素也有副作用。吸入胰岛素可能会引起咳嗽和喉咙发炎。口服胰岛素可能与消化酵素相互作用或引起胃肠道问题。患者不愿意使用非注射胰岛素产品是该市场成长的主要障碍。即使非注射胰岛素替代品有明显的优势和易用性，有些人仍不愿放弃舒适且公认的胰岛素注射方法。

糖尿病盛行率上升

随着糖尿病在世界各地变得越来越普遍，替代胰岛素输送系统也越来越普及。对于不愿意注射或註射有困难的糖尿病患者来说，非注射替代品可能是个令人信服的替代品。向患者、医疗保健专业人员和公众宣传非注射胰岛素解决方案的可用性和优点的倡议也推动了采用率的提高和市场扩张。

高成本

如果核准，非注射胰岛素的成本可能会比传统的注射胰岛素更高。由于输送系统的研发和技术进步，成本可能会增加。然而，监管机构在开发和核准非注射胰岛素方面遇到了困难。通常需要进行监管审查和长期临床试验，以确保一般用途的安全性和有效性。这些因素阻碍了市场扩张。

COVID-19 的影响：

非注射胰岛素市场受到 COVID-19 大流行的各种影响。儘管最初出现供应链中断和医疗保健设施有限的情况，但对糖尿病治疗创新解决方案的需求仍在增加。随着患者寻找替代品以减少就诊次数，对非注射胰岛素产品的需求增加。此外，这种流行病加速了远端医疗的使用，使患者更容易获得并与医疗保健专业人员讨论这些选择。

喷雾产业预计在预测期内规模最大

由于喷雾剂的便利性和对患者友好的特性，预计在预测期内将增长最大。寻求一种更简单、更少令人不快的方法来控製糖尿病的患者可能会发现吸入式胰岛素喷雾剂作为注射的侵入性较小的替代品很有吸引力。此外，随着药物传递技术的重大发展，这些喷雾可确保准确且有效的剂量。

医院药房业务预计在预测期内复合年增长率最高

医院药房业务预计在预测期内复合年增长率最高。医疗机构在糖尿病的管理和治疗中发挥着至关重要的作用，也是提供非注射胰岛素产品的重要中心。医院的临床背景增强了人们对非注射胰岛素製剂的信心。这种变数的组合使得医院药房普及和提供非注射胰岛素製剂，从而使广泛的患者群体受益。

比最大的地区

预计北美在预测期内将占据最大的市场占有率。该地区的糖尿病患病率高、医疗基础设施强大以及对研究和创新的重视造就了其优势。特别值得注意的是患者对改用非注射胰岛素产品的意识和准备程度。该地区对方便且以患者为中心的糖尿病治疗解决方案的强烈需求巩固了该地区巨大的市场占有率。

复合年增长率最高的地区：

预计亚太地区在预测期内复合年增长率最高。该地区糖尿病患病率高、都市化速度快、医疗基础设施不断扩大，导致对创新糖尿病管理解决方案的需求增加。政府倡议以及与製药公司的合作伙伴关係正在进一步支持市场扩张。由于我们庞大且多样化的患者群体以及令人鼓舞的医疗保健计划，这使我们成为该市场的重要参与者。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球非注射胰岛素市场：按产品

  • 口服
  • 经皮的
  • 鼻腔
  • 舌下
  • 其他产品

第六章全球非注射胰岛素市场：按剂量

  • 药丸
  • 喷

第七章全球非注射胰岛素市场：按分销管道

  • 医院药房
  • 网路商店
  • 药局

第八章全球非注射胰岛素市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第九章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司简介

  • Generex Biotechnology Corp.
  • Biodel, Inc.
  • Oramed Pharmaceuticals, Inc.
  • Diasome Pharmaceuticals, Inc.
  • Midatech Pharma Plc
  • Shreya Life Sciences Pvt. Ltd.
  • Boston Therapeutics, Inc.
  • Diabetology Ltd.
  • Emisphere Technologies, Inc.
  • Coromed, Inc.
  • Novo Nordisk
  • Sanofi
  • Eli Lilly
  • MannKind Corporation
  • Adocia
  • Oramed Pharmaceuticals
  • Dance Biopharm
  • Biocon
  • Janssen Pharmaceuticals
Product Code: SMRC24802

According to Stratistics MRC, the Global Non-Injectable Insulin Market is accounted for $1.4 billion in 2023 and is expected to reach $4.0 billion by 2030 growing at a CAGR of 15.2% during the forecast period. Non-injectable insulin refers to forms of insulin that do not require injection through a needle into the skin but instead can be administered through alternative methods. These techniques can be applied topically as patches or through inhalation, oral medication, or nasal sprays. With the introduction of non-injectable insulin, people who need insulin therapy will have more convenient options, which could lead to better treatment adherence and an overall improvement in quality of life.

According to Biocon, it terminated its phase 1 trial of oral Insulin Tregopil for Type 1 diabetes mellitus in June 2022, while continuing phase 3 trials for Type 2 diabetes mellitus

Market Dynamics:

Driver:

Technological developments in medicine delivery

The continuous progress in medication delivery technology is a major driver of the market's growth. The field of diabetes management is changing as a result of these innovative technical advancements, which make non-injectable insulin substitutes more dependable, efficient, and appealing to patients and medical professionals alike. Furthermore, these developments have improved insulin dose accuracy and consistency, increasing the overall effectiveness of non-injectable insulin devices.

Restraint:

Side effects

Like any medication, non-injectable insulin can have side effects. Inhaled insulin might cause coughing or throat irritation. Oral insulin might interact with digestive enzymes or cause gastrointestinal issues. The reluctance of patients to embrace non-injectable insulin techniques presents a significant obstacle to the market's growth. Even with the obvious benefits and ease of use of non-injectable insulin alternatives, some people are reluctant to abandon the comfortable and well-recognized method of insulin injections.

Opportunity:

Rising diabetes prevalence

Alternative insulin administration systems are becoming more and more popular as diabetes becomes more commonplace worldwide. Non-injectable alternatives present a compelling substitute for diabetes individuals who may be uncomfortable with or struggle with injections. Increased adoption and market expansion are also facilitated by initiatives to inform patients, medical professionals, and the general public about the availability and advantages of non-injectable insulin solutions.

Threat:

High cost

If approved, non-injectable insulin may cost more than conventional injectable insulin. Expenses may rise as a result of R&D and technological advancements in delivery systems. Regulators have encountered difficulties with the development and approval of non-injectable insulin, though. Regulatory scrutiny and lengthy clinical trials are frequently necessary to ensure safety and efficacy for general use. The market's expansion is being hindered by these factors.

Covid-19 Impact:

The market for non-injectable insulin has been affected by the COVID-19 pandemic in a variety of ways. The initial interruption of the supply chain and limited accessibility to healthcare facilities notwithstanding, there was an increasing demand for creative solutions to treat diabetes. There was an increase in demand for non-injectable insulin options as patients looked for alternatives to lessen their hospital visits. In addition, the epidemic hastened the use of telemedicine, facilitating patient access to and discussion of these choices with medical professionals.

The sprays segment is expected to be the largest during the forecast period

The sprays segment is expected to be the largest during the forecast period due to its convenience and patient-friendly attributes. Patients looking for simpler and less unpleasant ways to manage their diabetes may find inhalable insulin sprays appealing as a less intrusive substitute for injections. Furthermore, these sprays guarantee accurate and efficient dosage due to notable developments in drug delivery technology.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period. Healthcare facilities play a pivotal role in the management and treatment of diabetes, rendering them notable hubs for the delivery of insulin products that are not injectable. Trust in non-injectable insulin alternatives is fostered by the clinical context of hospitals. A broad patient population can benefit from the promotion and provision of non-injectable insulin solutions by hospital pharmacy due to the confluence of these variables.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. High diabetes prevalence, a robust healthcare infrastructure, and a strong emphasis on research and innovation in the region contribute to its prominence. Notable are the patient's awareness and readiness to switch to non-injectable insulin substitutes. The region's significant market share is cemented by the high need for accessible and patient-focused diabetes treatment solutions.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The region's high diabetes prevalence, rapid urbanization, and expanding healthcare infrastructure have contributed to increased demand for innovative diabetes management solutions. Initiatives from the government and partnerships with pharmaceutical firms have further encouraged market expansion. Because of this, it is positioned as a significant player in the market thanks to its large and diverse patient population and encouraging healthcare programs.

Key players in the market

Some of the key players in Non-Injectable Insulin market include Generex Biotechnology Corp., Biodel, Inc., Oramed Pharmaceuticals, Inc., Diasome Pharmaceuticals, Inc., Midatech Pharma Plc, Shreya Life Sciences Pvt. Ltd., Boston Therapeutics, Inc., Diabetology Ltd., Emisphere Technologies, Inc., Coromed, Inc., Novo Nordisk, Sanofi, Eli Lilly, MannKind Corporation, Adocia, Oramed Pharmaceuticals, Dance Biopharm, Biocon and Janssen Pharmaceuticals.

Key Developments:

In November 2023, Eli Lilly and Company announced plans to construct a new $2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate, Germany. This new facility will further expand the company's global parenteral (injectable) product and device manufacturing network and support an increased demand for Lilly's medicines, including its diabetes and obesity portfolio.

In February 2022, Biocon made a significant move by acquiring Viatris' biosimilar portfolio for a substantial sum of USD 3.335 billion. This strategic acquisition bolstered Biocon's biosimilar product offerings and had a positive impact on the company's revenue generation.

Products Covered:

  • Oral
  • Transdermal
  • Nasal
  • Sublingual
  • Other Products

Dosages Covered:

  • Pills
  • Sprays

Distribution Channels Covered:

  • Hospital Pharmacies
  • Online Stores
  • Drug Stores

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Non-Injectable Insulin Market, By Product

  • 5.1 Introduction
  • 5.2 Oral
  • 5.3 Transdermal
  • 5.4 Nasal
  • 5.5 Sublingual
  • 5.6 Other Products

6 Global Non-Injectable Insulin Market, By Dosage

  • 6.1 Introduction
  • 6.2 Pills
  • 6.3 Sprays

7 Global Non-Injectable Insulin Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Online Stores
  • 7.4 Drug Stores

8 Global Non-Injectable Insulin Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Generex Biotechnology Corp.
  • 10.2 Biodel, Inc.
  • 10.3 Oramed Pharmaceuticals, Inc.
  • 10.4 Diasome Pharmaceuticals, Inc.
  • 10.5 Midatech Pharma Plc
  • 10.6 Shreya Life Sciences Pvt. Ltd.
  • 10.7 Boston Therapeutics, Inc.
  • 10.8 Diabetology Ltd.
  • 10.9 Emisphere Technologies, Inc.
  • 10.10 Coromed, Inc.
  • 10.11 Novo Nordisk
  • 10.12 Sanofi
  • 10.13 Eli Lilly
  • 10.14 MannKind Corporation
  • 10.15 Adocia
  • 10.16 Oramed Pharmaceuticals
  • 10.17 Dance Biopharm
  • 10.18 Biocon
  • 10.19 Janssen Pharmaceuticals

List of Tables

  • Table 1 Global Non-Injectable Insulin Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Non-Injectable Insulin Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Non-Injectable Insulin Market Outlook, By Oral (2021-2030) ($MN)
  • Table 4 Global Non-Injectable Insulin Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 5 Global Non-Injectable Insulin Market Outlook, By Nasal (2021-2030) ($MN)
  • Table 6 Global Non-Injectable Insulin Market Outlook, By Sublingual (2021-2030) ($MN)
  • Table 7 Global Non-Injectable Insulin Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 8 Global Non-Injectable Insulin Market Outlook, By Dosage (2021-2030) ($MN)
  • Table 9 Global Non-Injectable Insulin Market Outlook, By Pills (2021-2030) ($MN)
  • Table 10 Global Non-Injectable Insulin Market Outlook, By Sprays (2021-2030) ($MN)
  • Table 11 Global Non-Injectable Insulin Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 12 Global Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 13 Global Non-Injectable Insulin Market Outlook, By Online Stores (2021-2030) ($MN)
  • Table 14 Global Non-Injectable Insulin Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 15 North America Non-Injectable Insulin Market Outlook, By Country (2021-2030) ($MN)
  • Table 16 North America Non-Injectable Insulin Market Outlook, By Product (2021-2030) ($MN)
  • Table 17 North America Non-Injectable Insulin Market Outlook, By Oral (2021-2030) ($MN)
  • Table 18 North America Non-Injectable Insulin Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 19 North America Non-Injectable Insulin Market Outlook, By Nasal (2021-2030) ($MN)
  • Table 20 North America Non-Injectable Insulin Market Outlook, By Sublingual (2021-2030) ($MN)
  • Table 21 North America Non-Injectable Insulin Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 22 North America Non-Injectable Insulin Market Outlook, By Dosage (2021-2030) ($MN)
  • Table 23 North America Non-Injectable Insulin Market Outlook, By Pills (2021-2030) ($MN)
  • Table 24 North America Non-Injectable Insulin Market Outlook, By Sprays (2021-2030) ($MN)
  • Table 25 North America Non-Injectable Insulin Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 26 North America Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 27 North America Non-Injectable Insulin Market Outlook, By Online Stores (2021-2030) ($MN)
  • Table 28 North America Non-Injectable Insulin Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 29 Europe Non-Injectable Insulin Market Outlook, By Country (2021-2030) ($MN)
  • Table 30 Europe Non-Injectable Insulin Market Outlook, By Product (2021-2030) ($MN)
  • Table 31 Europe Non-Injectable Insulin Market Outlook, By Oral (2021-2030) ($MN)
  • Table 32 Europe Non-Injectable Insulin Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 33 Europe Non-Injectable Insulin Market Outlook, By Nasal (2021-2030) ($MN)
  • Table 34 Europe Non-Injectable Insulin Market Outlook, By Sublingual (2021-2030) ($MN)
  • Table 35 Europe Non-Injectable Insulin Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 36 Europe Non-Injectable Insulin Market Outlook, By Dosage (2021-2030) ($MN)
  • Table 37 Europe Non-Injectable Insulin Market Outlook, By Pills (2021-2030) ($MN)
  • Table 38 Europe Non-Injectable Insulin Market Outlook, By Sprays (2021-2030) ($MN)
  • Table 39 Europe Non-Injectable Insulin Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 40 Europe Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 41 Europe Non-Injectable Insulin Market Outlook, By Online Stores (2021-2030) ($MN)
  • Table 42 Europe Non-Injectable Insulin Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 43 Asia Pacific Non-Injectable Insulin Market Outlook, By Country (2021-2030) ($MN)
  • Table 44 Asia Pacific Non-Injectable Insulin Market Outlook, By Product (2021-2030) ($MN)
  • Table 45 Asia Pacific Non-Injectable Insulin Market Outlook, By Oral (2021-2030) ($MN)
  • Table 46 Asia Pacific Non-Injectable Insulin Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 47 Asia Pacific Non-Injectable Insulin Market Outlook, By Nasal (2021-2030) ($MN)
  • Table 48 Asia Pacific Non-Injectable Insulin Market Outlook, By Sublingual (2021-2030) ($MN)
  • Table 49 Asia Pacific Non-Injectable Insulin Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 50 Asia Pacific Non-Injectable Insulin Market Outlook, By Dosage (2021-2030) ($MN)
  • Table 51 Asia Pacific Non-Injectable Insulin Market Outlook, By Pills (2021-2030) ($MN)
  • Table 52 Asia Pacific Non-Injectable Insulin Market Outlook, By Sprays (2021-2030) ($MN)
  • Table 53 Asia Pacific Non-Injectable Insulin Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 54 Asia Pacific Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 55 Asia Pacific Non-Injectable Insulin Market Outlook, By Online Stores (2021-2030) ($MN)
  • Table 56 Asia Pacific Non-Injectable Insulin Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 57 South America Non-Injectable Insulin Market Outlook, By Country (2021-2030) ($MN)
  • Table 58 South America Non-Injectable Insulin Market Outlook, By Product (2021-2030) ($MN)
  • Table 59 South America Non-Injectable Insulin Market Outlook, By Oral (2021-2030) ($MN)
  • Table 60 South America Non-Injectable Insulin Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 61 South America Non-Injectable Insulin Market Outlook, By Nasal (2021-2030) ($MN)
  • Table 62 South America Non-Injectable Insulin Market Outlook, By Sublingual (2021-2030) ($MN)
  • Table 63 South America Non-Injectable Insulin Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 64 South America Non-Injectable Insulin Market Outlook, By Dosage (2021-2030) ($MN)
  • Table 65 South America Non-Injectable Insulin Market Outlook, By Pills (2021-2030) ($MN)
  • Table 66 South America Non-Injectable Insulin Market Outlook, By Sprays (2021-2030) ($MN)
  • Table 67 South America Non-Injectable Insulin Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 68 South America Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 69 South America Non-Injectable Insulin Market Outlook, By Online Stores (2021-2030) ($MN)
  • Table 70 South America Non-Injectable Insulin Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 71 Middle East & Africa Non-Injectable Insulin Market Outlook, By Country (2021-2030) ($MN)
  • Table 72 Middle East & Africa Non-Injectable Insulin Market Outlook, By Product (2021-2030) ($MN)
  • Table 73 Middle East & Africa Non-Injectable Insulin Market Outlook, By Oral (2021-2030) ($MN)
  • Table 74 Middle East & Africa Non-Injectable Insulin Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 75 Middle East & Africa Non-Injectable Insulin Market Outlook, By Nasal (2021-2030) ($MN)
  • Table 76 Middle East & Africa Non-Injectable Insulin Market Outlook, By Sublingual (2021-2030) ($MN)
  • Table 77 Middle East & Africa Non-Injectable Insulin Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 78 Middle East & Africa Non-Injectable Insulin Market Outlook, By Dosage (2021-2030) ($MN)
  • Table 79 Middle East & Africa Non-Injectable Insulin Market Outlook, By Pills (2021-2030) ($MN)
  • Table 80 Middle East & Africa Non-Injectable Insulin Market Outlook, By Sprays (2021-2030) ($MN)
  • Table 81 Middle East & Africa Non-Injectable Insulin Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 82 Middle East & Africa Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 83 Middle East & Africa Non-Injectable Insulin Market Outlook, By Online Stores (2021-2030) ($MN)
  • Table 84 Middle East & Africa Non-Injectable Insulin Market Outlook, By Drug Stores (2021-2030) ($MN)